Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

RXi Pharmaceuticals Celebrates Expansion of its Operations in Massachusetts

Published: Saturday, July 05, 2014
Last Updated: Saturday, July 05, 2014
Bookmark and Share
Official opening of Company’s new office and laboratory in the Marlborough Technology Center.

RXi Pharmaceuticals Corporation has announced the official opening of its new office and laboratory in the Marlborough Technology Center. The Company will host a ribbon-cutting ceremony on Wednesday, July 9, 2014 from 10:00 -12:00 p.m., at 257 Simarano Drive, Marlborough, MA, to mark the opening of their new facility. The ceremony will be held in collaboration with the Massachusetts Life Sciences Center (MLSC) and MassBio.

"The Company's recent move to Marlborough has allowed us to centralize our employee base," said Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals. "In addition, this facility allows for future growth considerations as we advance our pre-clinical and clinical programs."

RXi Pharmaceuticals was founded in 2011. Since that time, the Company has successfully completed and announced positive results from two Phase 1 clinical studies with our lead compound RXI-109. We have formed two therapeutic franchises, within RXi, based on our areas of focus: Dermatology and Ophthalmology. The Company has continued to progress its dermal clinical program and is currently conducting two Phase 2 studies with a third study planned for initiation this year.

Within our Ophthalmology program, we have obtained positive results, with RXI-109, in the eyes of cynomolgus monkeys. In addition, the Company received a notice of allowance from the United States Patent and Trademark Office (USPTO) for a key patent covering our core, self-delivering RNAi technology (sd-rxRNA®) platform, which sets us apart from the competition and provides us with a powerful advantage to deliver our RNAi compounds without delivery vehicles. We believe we are well positioned for continued success.

The Company is supported by a group of dedicated, professional employees, with strategic guidance provided by a seasoned and successful Board of Directors, and by an accomplished Management and Scientific Advisory Board with significant experience in RNAi therapeutics, dermatology drug development and in building and managing emerging life science companies.

"Thanks to our growth strategy of investing in education, innovation and infrastructure, Massachusetts continues to lead the world in life sciences," said Massachusetts Governor Deval Patrick. "We congratulate RXi Pharmaceuticals on their expansion and look forward to their continued contributions to our thriving life sciences community."

"On behalf of the Center, I would like to extend our warmest congratulations to RXi Pharmaceuticals as the company officially opens its new office and laboratory in Marlborough," said Susan Windham Bannister, Ph.D., President and CEO of the Massachusetts Life Sciences Center, the agency charged with implementing Governor Patrick's 10-year, $1 billion Life Sciences Initiative. "We've enjoyed a long-standing relationship with RXi, and we are pleased to celebrate its ongoing success and growth in Massachusetts."


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

RXi Pharmaceuticals Granted US Notice of Allowance Covering Self-Delivering RNAi Platform
Patent will be scheduled to expire in 2029.
Saturday, May 24, 2014
RXi Pharmaceuticals Announces Initiation of First Clinical Trial
First subject was safely dosed with RXI-109, a self-delivering RNAi compound designed to reduce dermal carring.
Thursday, June 28, 2012
Scientific News
RNAi Screening Trends
Understand current trends and learn which application areas are expected to gain in popularity over the next few years.
New Material Opens Possibilities for Super-Long-Acting Pills
A pH-responsive polymer gel could create swallow able devices, including capsules for ultra-long drug delivery.
New Tool For Investigating RNA Gone Awry
A new technology – called “Sticky-flares” – developed by nanomedicine experts at Northwestern University offers the first real-time method to track and observe the dynamics of RNA distribution as it is transported inside living cells.
Access Denied: Leukemia Thwarted by Cutting Off Link to Environmental Support
A new study reveals a protein’s critical – and previously unknown -- role in the development and progression of acute myeloid leukemia (AML), a fast-growing and extremely difficult-to-treat blood cancer.
New Weapon in the Fight Against Blood Cancer
This strategy, which uses patients’ own immune cells, genetically engineered to target tumors, has shown significant success against multiple myeloma, a cancer of the plasma cells that is largely incurable.
TOPLESS Plants Provide Clues to Human Molecular Interactions
Scientists at Van Andel Research Institute have revealed an important molecular mechanism in plants that has significant similarities to certain signaling mechanisms in humans, which are closely linked to early embryonic development and to diseases such as cancer.
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
Scientists Create CRISPR/Cas9 Knock-In Mutations in Human T Cells
In a project spearheaded by investigators at UC San Francisco, scientists have devised a new strategy to precisely modify human T cells using the genome-editing system known as CRISPR/Cas9.
Long-sought Discovery Fills in Missing Details of Cell 'Switchboard'
A biomedical breakthrough reveals never-before-seen details of the human body’s cellular switchboard that regulates sensory and hormonal responses.
Tracking Breast Cancer Before it Grows
A team of scientists led by University of Saskatchewan researcher Saroj Kumar is using cutting-edge Canadian Light Source techniques to screen and treat breast cancer at its earliest changes.
SELECTBIO

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!